These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 33098638)

  • 1. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance.
    Feng J; Wen T; Li Z; Feng L; Zhou L; Yang Z; Xu L; Shi S; Hou K; Shen J; Han X; Teng Y
    Aging (Albany NY); 2020 Oct; 12(20):20658-20683. PubMed ID: 33098638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carcinogenic roles of MAFG-AS1 in human cancers.
    Ahmadi M; Morshedzadeh F; Ghaderian SMH; Mousavi P; Habibipour L; Peymani M; Abbaszadegan MR; Ghafouri-Fard S
    Clin Transl Oncol; 2024 Jan; 26(1):52-68. PubMed ID: 37351806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA MAFG-AS1 is involved in human cancer progression.
    Li P; Ma X; Gu X
    Eur J Med Res; 2023 Nov; 28(1):497. PubMed ID: 37941063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA MAFG-AS1 affects the tumorigenesis of breast cancer cells via the miR-574-5p/SOD2 axis.
    Dai J; Zhang S; Sun H; Wu Y; Yan M
    Biochem Biophys Res Commun; 2021 Jun; 560():119-125. PubMed ID: 33989902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.
    Ward A; Shukla K; Balwierz A; Soons Z; König R; Sahin O; Wiemann S
    J Pathol; 2014 Aug; 233(4):368-79. PubMed ID: 24752803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer.
    Osborne CK; Schiff R
    Breast; 2003 Dec; 12(6):362-7. PubMed ID: 14659106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MICAL-L2, as an estrogen-responsive gene, is involved in ER-positive breast cancer cell progression and tamoxifen sensitivity via the AKT/mTOR pathway.
    Wen P; Li J; Wen Z; Guo X; Ma G; Hu S; Xu J; Zhao H; Li R; Liu Y; Wang Y; Gao J
    Biochem Pharmacol; 2024 Jul; 225():116256. PubMed ID: 38729448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4.
    Ahmad A; Ginnebaugh KR; Yin S; Bollig-Fischer A; Reddy KB; Sarkar FH
    BMC Cancer; 2015 Jul; 15():540. PubMed ID: 26206152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.
    Nair BC; Vallabhaneni S; Tekmal RR; Vadlamudi RK
    Breast Cancer Res; 2011 Aug; 13(3):R80. PubMed ID: 21834972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway.
    Li Z; Yu D; Li H; Lv Y; Li S
    Int J Oncol; 2019 Mar; 54(3):1033-1042. PubMed ID: 30628639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
    Massarweh S; Schiff R
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
    Gutierrez MC; Detre S; Johnston S; Mohsin SK; Shou J; Allred DC; Schiff R; Osborne CK; Dowsett M
    J Clin Oncol; 2005 Apr; 23(11):2469-76. PubMed ID: 15753463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients.
    Egeland NG; Lunde S; Jonsdottir K; Lende TH; Cronin-Fenton D; Gilje B; Janssen EA; Søiland H
    Int J Mol Sci; 2015 Oct; 16(10):24243-75. PubMed ID: 26473850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
    Gee JM; Robertson JF; Gutteridge E; Ellis IO; Pinder SE; Rubini M; Nicholson RI
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S99-S111. PubMed ID: 16113104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206.
    Ren YQ; Wang HJ; Zhang YQ; Liu YB
    Cancer Chemother Pharmacol; 2017 May; 79(5):1003-1011. PubMed ID: 28391353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA OTUD6B-AS1 promotes paclitaxel resistance in triple negative breast cancer by regulation of miR-26a-5p/MTDH pathway-mediated autophagy and genomic instability.
    Li PP; Li RG; Huang YQ; Lu JP; Zhang WJ; Wang ZY
    Aging (Albany NY); 2021 Nov; 13(21):24171-24191. PubMed ID: 34740994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
    J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop.
    Li X; Wu Y; Liu A; Tang X
    Tumour Biol; 2016 Nov; 37(11):14733-14743. PubMed ID: 27629141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression.
    Niknafs YS; Han S; Ma T; Speers C; Zhang C; Wilder-Romans K; Iyer MK; Pitchiaya S; Malik R; Hosono Y; Prensner JR; Poliakov A; Singhal U; Xiao L; Kregel S; Siebenaler RF; Zhao SG; Uhl M; Gawronski A; Hayes DF; Pierce LJ; Cao X; Collins C; Backofen R; Sahinalp CS; Rae JM; Chinnaiyan AM; Feng FY
    Nat Commun; 2016 Sep; 7():12791. PubMed ID: 27666543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.